Archive

Research Deep DiveResearch Deep Dive
Healthcare M&A Sentiment: Optimism Returns, but Discipline Defines the Next Cycle

Healthcare M&A Sentiment: Optimism Returns, but Discipline Defines the Next Cycle

Healthcare M&A sentiment is improving as the industry moves toward 2026, supported by stabilizing financing markets, renewed strategic interest, and growing confidence that the post-2021 slowdown has largely bottomed out.

Weekly Round UpWeekly Round Up
Pharma’s China Dependency Is Becoming a Security Risk

Pharma’s China Dependency Is Becoming a Security Risk

Diving into the APAC Healthcare Bottleneck, GSK is acquiring Nuvalent for $10.6B in cash, marking the largest acquisition in the company’s history.

Weekly Round UpWeekly Round Up
Healthcare’s Next Wave Is Getting More Personalized

Healthcare’s Next Wave Is Getting More Personalized

Diving into the precision medicine market size, Medtech VC funding overview, Oncology dominators competitive landscape, and the increasing number of health and fitness apps usage

Research Deep DiveResearch Deep Dive
Precision Medicine 2030: The Convergence of Genomics, AI, and Personalized Care

Precision Medicine 2030: The Convergence of Genomics, AI, and Personalized Care

Precision medicine is rapidly transforming from a niche clinical concept into one of the defining trends shaping the future of healthcare and life sciences.

Weekly Round UpWeekly Round Up
What’s Blocking Healthcare M&A Right Now

What’s Blocking Healthcare M&A Right Now

Healthcare M&A hurdles, regional satisfaction gaps, and wearable tech’s clinical shift.

SurveysSurveys
What’s really holding back healthcare M&A?

What’s really holding back healthcare M&A?

Healthcare M&A Is Poised for a Recovery in 2026. The Industry Still Sees Three Structural Barriers Standing in the Way.

Weekly Round UpWeekly Round Up
Healthcare’s Next Margin Playbook Starts With AI

Healthcare’s Next Margin Playbook Starts With AI

Diving into the main cost drivers of Hospitals and the Healthcare Industry to understand what is the next margin playbook in the sector.

Research Deep DiveResearch Deep Dive
The Margin Playbook in an Era of Structural Cost Pressure

The Margin Playbook in an Era of Structural Cost Pressure

The healthcare industry has entered a new economic regime.

Weekly Round UpWeekly Round Up
The $10.7B Pharma Deal Reshaping European Healthcare

The $10.7B Pharma Deal Reshaping European Healthcare

We’re unpacking the forces slowing healthcare M&A acceleration in 2026, CVC’s €10.7B bet on European pharma, the rise of oral GLP-1 therapies as scalable healthcare infrastructure, and how Europe and Asia are emerging as a new global healthcare capital axis.

Weekly Round UpWeekly Round Up
Biopharma’s Great Reset Meets a Rural Staffing Squeeze

Biopharma’s Great Reset Meets a Rural Staffing Squeeze

We’re diving into the Biopharma reset, the share of new medicine reimbursement by public insurance, CMS scrutiny expansion, and rural healthcare PA cliff.

Research Deep DiveResearch Deep Dive
From Breakout Growth to Capital Discipline: Why Biopharma Returns Are Losing Momentum

From Breakout Growth to Capital Discipline: Why Biopharma Returns Are Losing Momentum

The biotechnology sector has long occupied a unique position within global capital markets.

Weekly Round UpWeekly Round Up
Biotech Is Back. And Healthcare PE Knows It

Biotech Is Back. And Healthcare PE Knows It

From biotech’s M&A momentum to home health consolidation and rising affordability risks, here’s what’s shaping healthcare strategy in 2026.

FirstBack
12345678
Next Last